By David Wild
Originally published by our sister publication, Gastroenterology Endoscopy News
Phase 3 study results show that a microbiome therapeutic consisting of purified Firmicutes spores reduced the risk for recurrent Clostridioides difficile infection (rCDI) by 59% compared with placebo six months after treatment for a prior CDI.